Navigation Links
NeoStem Announces Participation in Multiple October Conferences
Date:10/4/2011

NEW YORK, Oct. 4, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that the Company and its wholly-owned subsidiary, Progenitor Cell Therapy ("PCT"), will be presenting at three upcoming October conferences: the 2011 World Stem Cell Summit, the AABB Annual Meeting & CTTXPO, and Cell Therapy Bioprocessing.

2011 World Stem Cell Summit – October 3-5, 2011, Pasadena, California – Convention Center

3:45 PM on Tuesday, October 4 - Jason Kolbert, NeoStem's VP of Strategic Business Development, will moderate an industry session entitled "The Paradigm Shift to Cell Based Medicine: How Investors Can Discern True Value."  

12 PM on Wednesday, October 5 - Dr. Robin L. Smith, Chairman and CEO of NeoStem, Inc. will also speak at the World Stem Cell Summit in an industry session entitled "Financing Pathways for Stem Companies and Novel Funding Options."

AABB Annual Meeting & CTTXPO – October 22-25, 2011, San Diego, California – San Diego Convention Center

10:30 AM on Saturday, October 22 - Robert A. Preti, PhD, President and Chief Scientific Officer of PCT, will speak on a panel entitled "Cellular Therapy Product Development Using Project Management Techniques."

Cell Therapy Bioprocessing – October 17-18, 2011, Reston, Virginia – Hyatt Regency Reston

11:15 AM on Monday, October 17 - Karen Trujillo, BSc, Director of the Mountain View Facility for PCT, will give a presentation on the "Development of Lot Release Assays During Product Development."

Dr. Robin L. Smith said, "We are delighted to participate in this significant conference. In addition to sharing our knowledge of the industry, we consider this event an excellent platform to speak about our business lines. NeoStem endeavors to be an integrative force in the cell therapy industry. By vertically integrating the collection, storage and processing of cell units and the development, manufacturing, distribution, and delivery of cell therapy products, we are positioned to take advantage of growth in the cell therapy industry as a whole."

Jason Kolbert said, "As co-chair of a dynamic panel at the World Stem Cell Summit, I look forward to raising investors' awareness of the opportunities for cell therapy companies to continue to develop and create value in the healthcare system by bringing new cost-effective therapies that can address unmet medical needs to the marketplace. We have seen many paradigm shifts in the biotechnology industry from monoclonal antibodies to viral disease. We foresee cell therapy as among the next great opportunities in the biotechnology space and are thrilled to be adding to our clinical assets, through our Amorcyte, Inc. merger, AMR-001 for the preservation of heart function post heart attack as we believe this will be an important asset that will help drive this paradigm shift."

Robert A. Preti, PhD, said, "PCT is excited to have these venues in the coming month to demonstrate our leadership in cell therapy development, manufacturing, quality assurance, regulatory consulting, and more. At PCT we embrace the need for regulation of cell therapies, and work constructively with the both the public and private sector where appropriate. With the development of NeoStem's cell therapeutics, we are taking the approach of developing therapies along the lines of more traditional drugs, so that the issues of potency, purity, identity, and stability - all of those components that pharmaceutical and biologics companies think about - are considered. It is in this regard that we value our relationships with professional associations such as AABB, whose membership is involved in the manufacture and distribution of living, licensed products for the healthcare community."  

About NeoStem, Inc.

NeoStem is a leader in the development and manufacturing of cell therapies. The Company's strategic combination of revenues with manufacturing through its subsidiary, Progenitor Cell Therapy, LLC and global reach has positioned the company for breakthroughs in the cell therapy industry. The acquisition of Amorcyte, Inc. (which is expected to close in the fourth quarter subject to shareholder approval) will position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy. NeoStem is also pursuing a T-cell therapeutic with potential in a range of auto-immune conditions and development of its VSEL™ Technology platform. For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's prospectus supplement filed with the Securities and Exchange Commission on September 30, 2011. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

For more information, please contact:

NeoStem, Inc.
Robin Smith, CEO
Phone: +1-212-584-4174
Email: rsmith@neostem.com
Web:   http://www.neostem.com  


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSELā„¢ Technology Being Developed to Treat Osteoporosis
2. NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds
3. The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research
4. NeoStem to Present at Two Investor Events This Month
5. NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development
6. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
7. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
8. NeoStem Acquires Progenitor Cell Therapy
9. NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards
10. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
11. FOX Business Network Airing In-Depth Look at NeoStem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , ... April 27, 2016 , ... The Pittcon Organizing ... 2019. Chuck has been a volunteer member of Committee since 1987. Since then, ... board of directors and treasurer and was chairman for both the program and exposition ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, ... ) announced today that Martine Rothblatt , Ph.D., ... provide an overview and update on the company,s business ... Care Conference. The presentation will take place ... Time, and can be accessed via a live webcast ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding ... detection. , PathSensors deploys the CANARY® test platform for the detection of ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group and the ... as other research and development initiatives for potential stem cell protocol management for 2016 ... Cells Group executives began meeting to establish a working agenda and foster initiatives to ...
Breaking Biology Technology:
(Date:3/18/2016)... 2016 --> --> ... Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & ... the border security market and the continuing migration crisis in ... Europe has led visiongain to publish this unique ... --> defence & security companies in the border ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
Breaking Biology News(10 mins):